Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA -1.25%66 Cyclically Adjusted PS Ratio is 0.38 as of Jul. 21, 2026, which is 82% below its 10-year median of 2.06. GuruFocus rates USNA with a GF Score™ of 66/100 and a GF Value™ of $41.43 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,448 Consumer Packaged Goods companies, Usana Health Sciences ranks better than 70.79% on this metric.
The historical rank and industry rank for Usana Health Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:
USNA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.29 Med: 2.06 Max: 4.53
Current: 0.38
During the past years, Usana Health Sciences's highest Cyclically Adjusted PS Ratio was 4.53. The lowest was 0.29. And the median was 2.06.
USNA's Cyclically Adjusted PS Ratio is ranked better than 70.79% of 1448
companies
in the Consumer Packaged Goods industry
Industry Median: 0.765
vs USNA: 0.38
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Usana Health Sciences's adjusted revenue per share data for the three months ended in Mar. 2026 was $13.591. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $58.21 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Usana Health Sciences (NYSE:USNA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Usana Health Sciences Cyclically Adjusted PS Ratio Related Terms
Usana Health Sciences Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences Cyclically Adjusted PS Ratio Chart
USNA vs NATR, ENHA, BYND: Cyclically Adjusted PS Ratio Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Cyclically Adjusted PS Ratio falls into.
Usana Health Sciences Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.38 mean?
Usana Health Sciences (USNA) has a Cyclically Adjusted PS Ratio of 0.38 as of Jul. 21, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Usana Health Sciences and its competitors. This is 82% below median its historical median of 2.06. Over the past decade, Usana Health Sciences' Cyclically Adjusted PS Ratio has ranged from 0.29 to 4.53. According to the industry distribution chart, Usana Health Sciences ranks #423 out of 1448 companies in the Consumer Packaged Goods industry, placing it in the top 29.2%.
Is Usana Health Sciences' Cyclically Adjusted PS Ratio too high?
Usana Health Sciences' current Cyclically Adjusted PS Ratio of 0.38 is 82% below median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 4.53. The Consumer Packaged Goods industry median Cyclically Adjusted PS Ratio is 0.77. Usana Health Sciences' value of 0.38 is 50.3% below this industry median. Based on the distribution chart, Usana Health Sciences ranks #423 out of 1448 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Usana Health Sciences has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Cyclically Adjusted PS Ratio compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #423 out of 1448 companies for Cyclically Adjusted PS Ratio. This puts Usana Health Sciences in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.77. Usana Health Sciences' value of 0.38 is 50.3% below this benchmark. Historically, Usana Health Sciences' own Cyclically Adjusted PS Ratio has ranged from 0.29 to 4.53 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 0.77, Usana Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PS Ratio among Consumer Packaged Goods companies is 0.77, based on 1,448 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Cyclically Adjusted PS Ratio of 0.38 is 50.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PS Ratio is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Cyclically Adjusted PS Ratio is 0.38, which is 82% below median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $41.43, compared to a current price of $22.12 — trading 46.6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.38, which is 82% below median its 10-year median of 2.06 and 50.3% below the Consumer Packaged Goods industry median of 0.77. Usana Health Sciences' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current Cyclically Adjusted PS Ratio is 0.38 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $22.12 is trading 46.6% below its estimated GF Value™ of $41.43.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
Cyclically Adjusted PS Ratio: 0.38 (82% below median its 10-year median of 2.06)
GF Value™: $41.43 vs. price of $22.12 (46.6% below fair value)
Industry Position: 50.3% below the Consumer Packaged Goods median (#423 of 1448)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
66GF Score
Get the complete analysis for USNA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
